The immune mechanisms directly responsible for β-cell destruction in insulin-dependent diabetes are undefined. We studied the role of MHC class I–restricted T lymphocytes in the development of diabetes in cyclophosphamide (CY)-treated male and untreated female NOD mice (H-2Kd,Db). After administration of CY to 10-wk-old male NOD/Shi/Kbe mice, 37 of 64 (58%) phosphate-buffered saline–injected control mice and 13 of 22 (59%) anti-Kb and 12 of 27 (44%) anti-Db monoclonal antibody (MoAb)-injected mice became diabetic by 14 wk of age, whereas only 3 of 38 (8%) anti-Kd and 2 of 13 (15%) anti-Lyt-2 MoAb-injected mice did. In untreated female NOD/Shi/Kbe mice, 30 of 46 (65%) mice developed spontaneous diabetes by 30 wk of age, whereas none of 9 anti-Kd MoAb-injected mice became diabetic. Immunohistochemical studies showed that islet-infiltrating cells in CY-treated control mice were composed mainly of both L3T4+ and Lyt-2+ T lymphocytes, whereas many L3T4+ and very few Lyt-2+ lymphocytes infiltrated within the islets in anti-Kd MoAb-injected mice. Administration of anti-Lyt-2 MoAb induced the absence of Lyt-2+ T lymphocytes in the islet and spleen. However, anti-Kd MoAb did not change the number of spleen cells or the T-lymphocyte subset and response to concanavalin A. These results suggest that MHC class I Kd-restricted Lyt-2+ T lymphocytes play an important role as direct effector cells in destruction of β-cells in NOD/Shi/Kbe mice.
Skip Nav Destination
Article navigation
Original Articles|
September 01 1991
Prevention of Cyclophosphamide-Induced and Spontaneous Diabetes in NOD/Shi/Kbe Mice by Anti-MHC Class I Kd Monoclonal Antibody
Toshiya Taki;
Toshiya Taki
Second Department of Internal Medicine, Kobe University School of Medicine
Kobe
; and the Hyogo Institute for Research in Adult Diseases
Akashi, Japan
Search for other works by this author on:
Masao Nagata;
Masao Nagata
Second Department of Internal Medicine, Kobe University School of Medicine
Kobe
; and the Hyogo Institute for Research in Adult Diseases
Akashi, Japan
Search for other works by this author on:
Wataru Ogawa;
Wataru Ogawa
Second Department of Internal Medicine, Kobe University School of Medicine
Kobe
; and the Hyogo Institute for Research in Adult Diseases
Akashi, Japan
Search for other works by this author on:
Nobuo Hatamori;
Nobuo Hatamori
Second Department of Internal Medicine, Kobe University School of Medicine
Kobe
; and the Hyogo Institute for Research in Adult Diseases
Akashi, Japan
Search for other works by this author on:
Michiko Hayakawa;
Michiko Hayakawa
Second Department of Internal Medicine, Kobe University School of Medicine
Kobe
; and the Hyogo Institute for Research in Adult Diseases
Akashi, Japan
Search for other works by this author on:
Joji Hari;
Joji Hari
Second Department of Internal Medicine, Kobe University School of Medicine
Kobe
; and the Hyogo Institute for Research in Adult Diseases
Akashi, Japan
Search for other works by this author on:
Kozui Shii;
Kozui Shii
Second Department of Internal Medicine, Kobe University School of Medicine
Kobe
; and the Hyogo Institute for Research in Adult Diseases
Akashi, Japan
Search for other works by this author on:
Shigeaki Baba;
Shigeaki Baba
Second Department of Internal Medicine, Kobe University School of Medicine
Kobe
; and the Hyogo Institute for Research in Adult Diseases
Akashi, Japan
Search for other works by this author on:
Koichi Yokono
Koichi Yokono
Second Department of Internal Medicine, Kobe University School of Medicine
Kobe
; and the Hyogo Institute for Research in Adult Diseases
Akashi, Japan
Search for other works by this author on:
Address correspondence and reprint requests to Dr. Koichi Yokono, Second Department of Internal Medicine, Kobe University School of Medicine, Kobe 650, Japan.
Diabetes 1991;40(9):1203–1209
Article history
Received:
September 19 1990
Revision Received:
March 11 1991
Accepted:
March 11 1991
PubMed:
1936625
Citation
Toshiya Taki, Masao Nagata, Wataru Ogawa, Nobuo Hatamori, Michiko Hayakawa, Joji Hari, Kozui Shii, Shigeaki Baba, Koichi Yokono; Prevention of Cyclophosphamide-Induced and Spontaneous Diabetes in NOD/Shi/Kbe Mice by Anti-MHC Class I Kd Monoclonal Antibody. Diabetes 1 September 1991; 40 (9): 1203–1209. https://doi.org/10.2337/diab.40.9.1203
Download citation file:
53
Views